Gi Insights

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mark Pimentel, MD Small intestinal bacterial overgrowth (SIBO) can be a challenging condition to navigate due to the several controversies surrounding its testing and treatment. Joining Dr. Peter Buch to discuss these complex issues and controversies is Dr. Mark Pimentel, Director of the Medically Associated Science and Technology Program at Cedars Sinai in Los Angeles and author of the “ACG Clinical Guideline Small Intestinal Bacterial Overgrowth” article published in the American Journal of Gastroenterology in 2020.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Prateek Sharma, MD The evaluation and treatment of Barrett’s esophagus has been evolving over the last several years, but there are still many controversies and unanswered questions surrounding it. So to help answer some of these questions, Dr. Peter Buch speaks with Dr. Prateek Sharma, author of the “AGA Clinical Practice Update on Endoscopic Treatment of Barrett’s Esophagus with Dysplasia and/or Early Cancer Expert Review,” which was published in the Gastroenterology journal in 2020.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Asher A. Kornbluth, MD Since the onset of the COVID-19 pandemic, many questions have arisen regarding the care of our patients with IBD. Are they at increased risk of COVID-19? How should we treat a patient with IBD who has active COVID-19? Should they get vaccinated, and if so, when? These are all questions Dr. Peter Buch addresses with Dr. Asher Kornbluth, Clinical Professor of Medicine and Gastroenterology at Mount Sinai School of Medicine in New York, to help us optimize our approach to care amid the COVID-19 pandemic.

Host: Neilanjan Nandi, MD Guest: Jessica Allegretti, MD, MPH Bezlotoxumab is an IV antitoxin infusion treatment option for Clostridium difficile (C. diff) that’s been shown to reduce recurrence in IBD patients…so why isn’t it being used as much as it should be? Here to share the latest data and insights on bezlotoxumab as a treatment option for IBD patients with C. diff is Dr. Jessica Allegretti, Associate Director of the Crohn's and Colitis Center and Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.

Host: Neilanjan Nandi, MD Guest: Jessica Allegretti, MD, MPH Also known as C. diff for short, Clostridium difficile is an extremely difficult intestinal disease to manage…but not an impossible one. Joining Dr. Neil Nandi to share her insights on how to best mange C. diff in IBD patients is Dr. Jessica Allegretti, the Associate Director of the Crohn's and Colitis Center and the Director of the Fecal Microbiota Transplant Program at the Brigham and Women's Hospital in Boston, Massachusetts.

Host: Neilanjan Nandi, MD Guest: Kate Scarlata, MPH, RDN Many patients tailor their diets to their gastrointestinal disorders, such as IBS, and adopt a low FODMAP regimen. What skills do we need to help screen patients for FODMAP sensitivities and identify foods they should avoid? Dr. Neil Nandi will be discussing these skills with Kate Scarlata, a registered dietitian, and a New York Times best-selling author.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Laurie Keefer, PhD While diagnosing irritable bowel syndrome and inflammatory bowel disease is critical to care, treating these illnesses and improving quality of life is just as important. Joining Dr. Peter Buch to share strategies to help counsel and care for our patients beyond diagnosis is Dr. Laurie Keefer, Professor of Medicine, Gastroenterology, and Psychiatry at Mount Sinai School of Medicine.

Host: Neilanjan Nandi, MD Guest: Aline Charabaty, MD Many of us use social media to stay connected with family and friends. But have you ever considered using social media to communicate with other clinicians and even earn CME credit? Clinical Director of Gastroenterology and Director of the Inflammatory Bowel Disease Center at Sibley Memorial Hospital Dr. Aline Charabaty saw that opportunity and used it to create Monday Night IBD, and now Dr. Charabaty is here to talk about that program and the benefits of social media for clinicians with Dr. Neil Nandi.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Cynthia L Sears, M.D. Decreased resistance to antibiotics has adversely impacted our ability to fight H. pylori. How can we help our patients overcome this threat? Dr. Peter Buch is here today to discuss this issue with Dr. Cynthia Sears, professor of medicine at the Johns Hopkins University School of Medicine to help improve health outcomes for our patients.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Douglas Drossman, MD Guest: Johannah Ruddy, MEd Gender bias and trauma are prevalent issues that have far-reaching impacts on our GI patients’ health and even our diagnostic and treatment approaches. To learn more about how gender bias and trauma impact patients and clinicians alike, Dr. Peter Buch is joined by Dr. Douglas Drossman and patient advocate Ms. Johanna Ruddy from the Rome Foundation.

Host: Neilanjan Nandi, MD Guest: Austin Chiang, MD, MPH The field of endoscopic bariatric weight loss has developed over the years, but there’s a lot we still don’t know. Dr. Neil Nandi is here today with Dr. Austin Chiang, Director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, to provide some insight on advanced endoscopy for bariatric weight loss.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Arlene Wright, DNP, APRN, FNP-BC, FNAP Thanks to recent research and advancements, our understanding and treatment of gastroesophageal reflux disease (GERD) has greatly evolved over the years. So what do we now know about diagnosing and treating this common GI disorder? Find out with Dr. Peter Buch and Dr. Arlene Wright, President of the Florida Nurse Practitioner Network and Executive Vice President of the Nurse Practitioners of Lee County, Florida.

Host: Neilanjan Nandi, MD Guest: Freddy Caldera, DO Many IBD patients have received their COVID-19 vaccine, but many others still have reservations due to the abundance of myths and misconceptions surrounding the COVID-19 vaccines. That’s why Dr. Neil Nandi welcomes Dr. Freddy Caldera to discuss these common fears and challenges as well as some of the very best answers to address the concerns of our immunosuppressed IBD patients.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Rajeev Attam, MD Pancreatic cysts may be detected in up to 50 percent of patients undergoing intraabdominal MR imaging. But not all of them are malignant, so how can we determine which patients need further testing, monitoring, and perhaps even surgery? Joining Dr. Peter Buch to answer that and other questions is gastroenterologist Dr. Rajeev Attam.

Host: Neilanjan Nandi, MD Guest: David T. Rubin, MD With more data emerging on COVID-19 vaccines every day, what do our patients with inflammatory bowel disease need to know about the vaccine currently available? Dr. Neil Nandi will be discussing these updates and how we can keep our patients safe with Dr. David Rubin, Professor of Medicine at the University of Chicago Pritzker School of Medicine.

Host: Neilanjan Nandi, MD Guest: David T. Rubin, MD How has the COVID-19 pandemic impacted patients with IBD? Dr. Neil Nandi is here to answer our COVID-19 questions for our IBD patients with Dr. David Rubin, Professor of Medicine at the University of Chicago Pritzker School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Colin T. Swales, MD Should sobriety and drug abstinence be required for hepatitis C therapy? Dr. Peter Buch dives into this dilemma with Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital, as he walks us through both sides of this controversial issue.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Colin T. Swales, MD From cirrhosis to liver cancer, there are many dangers associated with non-alcoholic fatty liver disease. So what are some best practices for managing this condition? Dr. Peter Buch sits down with Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital, to discuss the management of non-alcoholic fatty liver disease.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Colin T. Swales, MD How can we help the two to four million Americans who are living with hepatitis C? Joining Dr. Peter Buch to answer this question and share treatment strategies for various case scenarios is hepatologist Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Adam Olsen, MS, PA-C Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.